Novartis Animal Health US, Inc. 3200 Northline Avenue Suite 300 Greensboro NC 27408
CONTACT: Joseph Burkett
?Novartis Animal Health US, Inc. Introduces VETSPON
Absorbable Hemostatic Gelatin Sponges
New Surgical Aid Provides Effective Advantages For Veterinarians
GREENSBORO, North Carolina (February 2, 2006) – Veterinarians now have an effective, ?and convenient way to control oozing bleeding during surgery using new VETSPON
Absorbable Hemostatic Gelatin Sponges from Novartis Animal Health US, Inc. The VETSPON products not only provide effective, quick and easy hemostasis during general surgery and dental procedures, they are designed exclusively for veterinary surgery.
“It’s rewarding to introduce a new product that has received consistently positive response
from veterinarians in early usage trials, and that’s been the case with new VETSPON Absorbable Hemostatic Gelatin Sponges,” says Novartis Animal Health US, Inc. Product Manager, Jason Drake, DVM.
Veterinarians who have used VETSPON say it performs better than other hemostasis products in several important ways:*
• Ease of use
• Efficacy in stopping bleeding
• Speed in stopping bleeding
• Product size
• Overall performance
Sterile, water-insoluble and pliable, VETSPON is available in two forms: Flex Absorbable Hemostatic Gelatin Sponge, U.S.P., and Dental Absorbable Hemostatic Gelatin Sponge, U.S.P. Veterinarians surveyed said they particularly like the flexibility to cut the VETSPON Flex sheet to the exact shape needed, and will likely use it in a variety of procedures, including tumor removals, biopsies, larger tooth extractions, and spay/neuter surgeries.*
Quick and effective hemostasis not only minimizes blood loss for the patient, it allows a surgeon to operate in a dry, clearly visible surgical field, which can save valuable surgical and anesthesia time. VETSPON can be used in all surgical procedures (except urologic and ophthalmic procedures) when venous and oozing bleeding occur and where traditional hemostasis is difficult or impractical. As one veterinary surgeon explained, “Hemostasis was excellent with VETSPON Flex, even for a problem case of a non-responsive hematoma that was previously corrected with surgery.”*
VETSPON, which can be used dry or moistened with sterile saline, is 100 percent absorbable, and will absorb biologically over a four-to-six week period if left in the body. Since it is implantable, VETSPON can help to prevent internal post-operative oozing, and the advantages are noticeable.
Veterinarians who tried VETSPON Dental in usage trials say they prefer it for dental extractions, as well.*
“Preventing or stopping bleeding is one of the most vital aspects of veterinary surgery, and VETSPON Absorbable Hemostatic Gelatin Sponges give veterinarians another vital option for more successful surgical outcomes,” says Andy Ferrigno, Novartis Animal Health US, Inc. Director of Marketing.
“That’s why we’re encouraging veterinarians to review the benefits of VETSPON, and to call
their local Novartis Animal Health US, Inc., sales representative or authorized distributor for details on how to try these products.”
Distributed by Novartis Animal Health US, Inc., VETSPON is developed and manufactured by Ferrosan A/S, which has been in the medical device market with gelatin-based hemostasis products since 1947. Supplied in two forms, VETSPON Dental Cube comes in boxes of 16 cubes (each 1 cm x 1 cm x 1 cm), while VETSPON Flex Sheet is available in boxes of 6 sheets (each 2 cm x 6 cm x 0.7 cm). (See attached product insert for more information.)
Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2004, the Group’s businesses achieved sales of USD 28.2 billion and a net income of USD 5.8 billion. The Group invested approximately USD 4.2 billion in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ about 81,400 people and operate in over 140 countries around the world. For further information, consult http://www.novartis.com.
Novartis Animal Health researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Headquartered in Basel, Switzerland; and present in almost 40 countries, Novartis Animal Health employs about 2,200 people worldwide and achieved sales of USD 756 million in 2004. For more information, please consult www.ah.novartis.com.
### VETSPON is a registered trademark of Ferrosan A/S.
VETSPON In-Clinic Evaluation Study, Forward Research, July 2005 *